Home
Random
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Aptahem AB
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Summary<ref>Source: Yahoo Finance.</ref> == Aptahem AB (publ), a biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in pre-clinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various consultants and contract research laboratories, including The Nencki Institute of Experimental Biology, BioSpring, Red Glead Discovery, SmiLe Incubator, Truly Translational Sweden AB, Axolabs, Accelera, PKxpert AB, Hooke Laboratories; Cardiovascular Research Centre; and Ã-rebro University. Aptahem AB (publ) was founded in 2014 and is based in Malmö, Sweden. == References and notes == [[Category:Thesis]] __INDEX__
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
